Show simple item record

dc.contributor.authorMoreno-Torres, Irene
dc.contributor.authorMeca Lallana, Virginia
dc.contributor.authorCosta-Frossard, Lucienne
dc.contributor.authorOreja-Guevara, Celia
dc.contributor.authorAguirre, Clara
dc.contributor.authorSuárez, Elda María Alba
dc.contributor.authorGómez Moreno, Mayra
dc.contributor.authorBorrega Canelo, Laura
dc.contributor.authorSabín‑Muñoz, Julia
dc.contributor.authorAladro, Yolanda
dc.contributor.authorCárcamo, Alba
dc.contributor.authorRodríguez García, Elena
dc.contributor.authorCuello, Juan Pablo
dc.contributor.authorMonreal, Enric
dc.contributor.authorSainz de la Maza, Susana
dc.contributor.authorPérez Parra, Fernando
dc.contributor.authorValenzuela Rojas, Francisco
dc.contributor.authorLópez de Silanes de Miguel, Carlos
dc.contributor.authorCasanova, Ignacio
dc.contributor.authorMartínez Gines, Maria Luisa
dc.contributor.authorBlasco, Rosario
dc.contributor.authorOrviz García, Aida
dc.contributor.authorVillar-Guimerans, Luisa María
dc.contributor.authorFernández-Dono, Guillermo
dc.contributor.authorElvira, Víctor
dc.contributor.authorSantiuste, Carmen
dc.contributor.authorEspiño, Mercedes
dc.contributor.authorGarcía Domínguez, José Manuel
dc.description.abstractBackground and purpose Limited information is available on incidence and outcomes of COVID-19 in patients with multiple sclerosis (MS). This study investigated the risks of SARS-CoV-2 infection and COVID-19-related outcomes in patients with MS, and compared these with the general population. Methods A regional registry was created to collect data on incidence, hospitalization rates, intensive care unit admission, and death in patients with MS and COVID-19. National government outcomes and seroprevalence data were used for comparison. The study was conducted at 14 specialist MS treatment centers in Madrid, Spain, between February and May 2020. Results Two-hundred nineteen patients were included in the registry, 51 of whom were hospitalized with COVID-19. The mean age ± standard deviation was 45.3 ± 12.4 years, and the mean duration of MS was 11.9 ± 8.9 years. The infection incidence rate was lower in patients with MS than the general population (adjusted incidence rate ratio = 0.78, 95% confidence interval [CI] = 0.70–0.80), but hospitalization rates were higher (relative risk = 5.03, 95% CI = 3.76–6.62). Disease severity was generally low, with only one admission to an intensive care unit and five deaths. Males with MS had higher incidence rates and risk of hospitalization than females. No association was found between the use of any disease-modifying treatment and hospitalization risk. Conclusions Patients with MS do not appear to have greater risks of SARS-CoV-2 infection or severe COVID-19 outcomes compared with the general population. The decision to start or continue disease-modifying treatment should be based on a careful risk–benefit
dc.publisherEuropean Journal of Neurologyspa
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.subjectMultiple sclerosisspa
dc.subjectSevere acute respiratory syndrome coronavirus 2spa
dc.titleRisk and outcomes of COVID-19 in patients with multiple
dc.typejournal articlespa
dc.rights.accessRightsmetadata only accessspa
dc.description.extent996 KBspa

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 3.0 España
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 España